Uremic and Dialysis Encephalopathies

  • Allen I. Arieff


Because of advancements in dialysis therapy and renal transplantation, and their medical management, patients with end-stage renal disease (ESRD) rarely develop severe clinical manifestations before the institution of therapy. In the USA, there are currently about 450,000 patients receiving dialysis therapy (Meyer & Hostetter, 2007). Although uncommon in the USA and Canada, patients who have chronic renal failure (GFR below 30 ml/min) and have not yet received dialysis therapy may develop a symptom complex characterized by fatigue, mild sensorial clouding, decreased mental acuity, tremor, anorexia, nausea and sleep disturbances (Gusbeth-Tatomir et al., 2007; Perl et al., 2006;). However, the institution of apparently adequate maintenance dialysis therapy does not eliminate central nervous system (CNS) manifestations of uremia. CSN disorders of both untreated renal failure and those persisting despite dialysis are referred to as uremic encephalopathy. The treatment of end stage renal disease with dialysis has itself been associated with the emergence of several distinct disorders of the central nervous system. These disorders are: dialysis disequilibrium syndrome, dialysis dementia, stroke, sexual dysfunction and a new syndrome of chronic dialysis-dependent encephalopathy (Arieff, 2004).


Acute Renal Failure Chronic Renal Failure Subdural Hematoma Chronic Hemodialysis Uremic Patient 
These keywords were added by machine and not by the authors. This process is experimental and the keywords may be updated as the learning algorithm improves.


  1. Abdel-Gawad M, Huynh H & Brock GB. (1999). Experimental chronic renal failure-asociated erectile dysfunction: Molecular alterations in nitric oxide synthetase pathway and IGF-I system. Molecular Urol 3, 117–125.Google Scholar
  2. Akmal M, Goldstein DA, Multani S & Massry SG. (1984). Role of uremia, brain calcium and parathyroid hormone on changes in electroencephalogram in chronic renal failure. Am J Physiol 246 (Renal, Fluid, Electrolyte Physiol. 15), F575–F579.PubMedGoogle Scholar
  3. Albaaj F & Hutchison AJ. (2005). Lanthanum carbonate for the treatment of hyperphosphatemia in renal failure and dialysis patients. Expert Opin Pharmacother 6, 319–328.PubMedGoogle Scholar
  4. Albers GW, Atkinson RP, Kelley RE & Rosenbaum DM. (1995). Safety, tolerability and pharmacokinetics of the NMDA antagonist dextrorphan in patients with acute stroke. Stroke 26, 254–258.PubMedGoogle Scholar
  5. Alfrey AC, LeGendre GR & Kaehny WD. (1976). The dialysis encephalopathy syndrome: Possible aluminum intoxication. N Engl J Med 294, 184–188.PubMedGoogle Scholar
  6. Alfrey AC, Mishell J, Burks SR, Contiguglia SR, Rudolph H, Lewin E & Holmes JH. (1972). Syndrome of dysphaxia and multifocal seizures associated with chronic hemodialysis. Trans Amer Soc Artif Intern Organs 18, 257–261.Google Scholar
  7. ALLHAT. (2002). Major outcomes in high-risk hypertensive patients randomized to angiotensin-converting enzyme inhibitor or calcium channel blocker vs diuretic. JAMA 288, 2981–2997.Google Scholar
  8. Altmann P, Al-Salihi F, Butter K, Cutler P, Blair J, Leeming R, Cunningham J & Marsh F. (1987). Serum aluminum levels and erythrocyte dihydropteridine reductase activity in patients on hemodialysis. N Engl J Med 317, 80–84.PubMedGoogle Scholar
  9. Altmann P, Hamon C, Blair J, Dhanesha U, Cunningham J & Marsh F. (1989). Disturbance of cerebral function by aluminum in haemodialysis patients without overt aluminum toxicity. Lancet ii, 7–12.Google Scholar
  10. Amarenco P, Duyckaerts C, Tzourio C, Henin D, Bousser MG & Hauw JJ. (1992). The prevalence of ulcerated plaques in the aortic arch in patients with stroke. New Engl J Med 326, 221–225.PubMedGoogle Scholar
  11. Andreoli SP, Bergstein JM & Sherrard DJ. (1984). Aluminum intoxication from aluminum-containing phosphate binders in children with azotemia not undergoing dialysis. N Engl J Med 310, 1079.PubMedGoogle Scholar
  12. Arieff AI. (1982). Dialysis disequilibrium syndrome: Current concepts on pathogenesis. In Controversies in Nephrology, Schreiner GE & Winchester JF, pp. 367–376. George Washington University Press, Washington, D.C.Google Scholar
  13. Arieff AI. (1983). Dialysis disequilibrium syndrome. In Textbook of Nephrology, 1st edn, Massry SG & Glassock RJ, pp. 7.24–27.26. Williams & Wilkins, Baltimore.Google Scholar
  14. Arieff AI. (1985). Effects of water, acid base, and electrolyte disorders on the central nervous system. In Fluid, Electrolyte and Acid-Base Disorders, Arieff AI & DeFronzo RA, pp. 969–1040. Churchill Livingstone, New York.Google Scholar
  15. Arieff AI. (1986). Neurological manifestations of uremia. In The Kidney, 3rd edn, Brenner BM & Rector FC, Jr., pp. 1731–1756. W. B. Saunders, Philadelphia.Google Scholar
  16. Arieff AI. (1989). Dialysis disequilibrium syndrome. In Textbook of Nephrology, 2nd edn, Massry SG & Glassock RJ, pp. 1168–1170. Williams & Wilkins, Baltimore.Google Scholar
  17. Arieff AI. (1990). Aluminum and the pathogenesis of dialysis dementia. Environ Geochem Health 12, 89–93.Google Scholar
  18. Arieff AI. (1994). Dialysis disequilibrium syndrome: Current concepts on pathogenesis and prevention. Kidney Int 45, 629–635.PubMedGoogle Scholar
  19. Arieff AI. (2004). Neurological complications of renal iInsufficiency. In Brenner & Rector’s The Kidney, 7th edn, Brenner BM, pp. 2227–2254. W.B. Saunders, Philadelphia.Google Scholar
  20. Arieff AI, Cooper JD, Armstrong D & Lazarowitz VC. (1979). Dementia, renal failure and brain aluminium. Ann Intern Med 90, 741–747.PubMedGoogle Scholar
  21. Arieff AI, Fraser CL, Rowley H, Truwit C & Kucharczyk J. (1994). Metabolic encephalopathy. In Magnetic Resonance Neuroimaging, 1st edn, Kucharczyk J, Moseley M & Barkovich AJ, pp. 319–349. CRC Press, Boca Raton, FL.Google Scholar
  22. Arieff AI, Guisado R & Massry SG. (1975). Uremic encephalopathy: Studies on biochemical alterations in the brain. Kidney Int 7, S194–S200.Google Scholar
  23. Arieff AI, Guisado R & Massry SG. (1977). Central nervous system pH in uremia and the effects of hemodialysis. J Clin Invest 58, 306.Google Scholar
  24. Arieff AI, Kerian A, Massry SG & DeLima J. (1976). Intracellular pH of brain: alterations in acute respiratory acidosis and alkalosis. Am J Physiol 230, 804–812.PubMedGoogle Scholar
  25. Arieff AI & Mahoney CA. (1983). Pathogenesis of dialysis encephalopathy. Neurobehav Toxicol Teratol 5, 641–644.PubMedGoogle Scholar
  26. Arieff AI & Massry SG. (1974). Calcium metabolism of brain in acute renal failure. Effects of uremia, hemodialysis, and parathyroid hormone. J Clin Invest 53, 387–392.PubMedGoogle Scholar
  27. Asahi K, Ichimori K, Nakaawa H & Izuhara Y. (2000). Nitric oxide inhibits the formation of advanced glycation end products. Kidney Int 58, 1780–1787.PubMedGoogle Scholar
  28. Ayus JC, Go AS, Valderrabano F, Verde E, De Vinuesa SG, Achinger SG, Lorenzo V, Arieff AI & Luno J. (2005). Effects of erythropoietin on left ventricular hypertrophy in adults with severe chronic renal failure and hemoglobin <10 g/dl. Kidney Int 68, 788–795.PubMedGoogle Scholar
  29. Ayus JC & Sheikh-Hamad D. (1998). Silent infection in clotted hemodialysis access grafts. J Am Soc Nephrol 9, 1314–1317.PubMedGoogle Scholar
  30. Banks WA & Kastin AJ. (1983). Aluminium increases permeability of the blood-brain barrier to labelled DSIP and b-endorphin: Possible implications for senile and dialysis dementia. Lancet, 1227–1229.Google Scholar
  31. Beal MF. (1992). Mechanisms of excitotoxicity in neurologic disease. FASEB J 6, 3338–3344.PubMedGoogle Scholar
  32. Bergstrom J & Furst P. (1983). Uremic toxins. In Replacement of Renal Function by Dialysis, Drukker W, Parsons FM & Maher JF, pp. 354–377. Martinus Nijhoff, Boston.Google Scholar
  33. Berkseth RO & Shapiro FL. (1980). An epidemic of dialysis encephalopathy and exposure to high aluminum dialysate. In Controversies in Nephrology, Schriener GE & Winchester JF, p. 42. Georgetown University Press, Georgetown, MD.Google Scholar
  34. Bleumle LW. (1968). Current status of chronic hemodialysis. Am J Med 44, 749.Google Scholar
  35. Bohlender JM, Franke S, Stein G & Wolf G. (2005). Advanced glycation end products and the kidney. Am J Physiol: Renal Physiol 289, F645–F659.Google Scholar
  36. Bolton CF. (1976). Electrophysiologic changes in uremic neuropathy after successful renal transplantation. N Engl J Med 284, 1170.Google Scholar
  37. Breyer JA, Bain RP, Evans JK, Nahman NS & Lewis EJ. (1996). Predictors of the progression of renal insufficiency in patients with insulin-dependent diabetes and overt diabetic nephropathy. Kidney Int 50, 1651–1658.PubMedGoogle Scholar
  38. Bronner IL, Kanter DS & Manson JE. (1995). Primary prevention of stroke. New Engl J Med 333, 1392–1400.PubMedGoogle Scholar
  39. Brott T & Bogousslavsky J. (2000). Treatment of acute ischemic stroke. New Engl J Med 343, 710–722.PubMedGoogle Scholar
  40. Brouns R & De Deyn PP. (2004). Neurological complications in renal failure: A review. Clin Neurol Neurosurg 107, 1–16.PubMedGoogle Scholar
  41. Brun A & Dictor M. (1981). Senile plaques and tangles in dialysis dementia. Acta Path Microbiol Scand Sect. A 89, 193–198.Google Scholar
  42. Burks JS, Alfrey AC, Huddlestone J, Norenberg MD & Lewin E. (1976). A fatal encephalopathy in chronic haemodialysis patients. Lancet 1, 764–768.PubMedGoogle Scholar
  43. Campbell IR, Cass JF & Cholak J. (1957). Aluminum in the enviornment of man. AMA Arch Indust Health 15, 359–361.Google Scholar
  44. Campese VM & Liu CL. (1990). Sexual dysfunction in uremia. Contrib Nephrol 77, 1–14.PubMedGoogle Scholar
  45. Campese VM, Romoff MS & Levitan D. (1981). Mechanisms of autonomic nervous system dysfunction in uremia. Kidney Int 20, 246.PubMedGoogle Scholar
  46. Candy JM, McArthur FK, Oakley AE, Taylor GA & Chen CP. (1992). Aluminum accumulation in relation to senile plaque and neurobibrillary tangle formation in the brains of patients with renal failure. J Neurol Sci 107, 210–218.PubMedGoogle Scholar
  47. Cartier F, Allain P, Gary J, Chatel M, Menault F & Pecker S. (1978). Encephalopathie myoclonique progressive des dialyses: Role de l’eau utilisee pour l’hemodialyse. Nouv Presse Med 7, 97–102.PubMedGoogle Scholar
  48. Chan L, Wang W & Kam I. (2001). Outcomes and complications of renal transplantation. In Diseases of the Kidney, 7th edn, Schrier RW & Gottschalk CW, pp. 2871–2938. J.B. Lippincott, Philadelphia.Google Scholar
  49. Chazan JA, Blonsky SL, Abuelo JG & Pezzullo JC. (1988). Increased body aluminum: An independent risk factor in patients undergoing long-term hemodialysis? Arch Intern Med 148, 1817–1820.PubMedGoogle Scholar
  50. Chen CL, Lai PH, Chou KJ, Chung HM & Fang HC. (2007). A preliminary report of brain edema in pateints with uremia at first hemodialysis: Evaluation by diffusion-weighted MR imaging. Am J Neuroradiol 28, 68–71.PubMedGoogle Scholar
  51. Clark WR & Gao D. (2002). Low-molecular weight proteins in end-stage renal disease: Potential toxicity and dialytic removal mechanisms. J Am Soc Nephrol 13, S41–S47.PubMedGoogle Scholar
  52. Cogan MG, Covey C, Arieff AI, Wisniewski A, Clark OH, Lazorowitz VC & Leach W. (1978). Central nervous system manifestations of hyperparathyroidism. Amer J Med 65, 963–970.PubMedGoogle Scholar
  53. Cohen H, Rdnicki M & Horl WH. (2001). Uremic toxins modulate the spontaneous apoptotic cell death and essential functions of neutrophils. Kidney Int 59 (Suppl. 78), S48–S52.Google Scholar
  54. Cooper JD & Arieff AI. (1979). Lindau disease treated by bilateral nephrectomy and hemodialysis. West J Med 130, 456–458.PubMedGoogle Scholar
  55. Cooper JD, Lazarowitz VC & Arieff AI. (1978). Neurodiagnostic abnormalities in patients with acute renal failure. Evidence for neurotoxicity of parathyroid hormone. J Clin Invest 61, 1448–1455.PubMedGoogle Scholar
  56. D’Hooge R, Van de Vijver G, Van Bogaert PP, Marescau B & Vanholder R. (2003). Involvement of voltage- and ligand-gated Ca2+ channels in the neuroexcitatory and synergistic efects of putative uremic neurotoxins. Kidney Int 63, 1764–1775.PubMedGoogle Scholar
  57. Davidoff F. (1968). Effects of guanidine derivatives on mitochrondial function I. J Clin Invest 47, 2331–2343.PubMedGoogle Scholar
  58. Davidoff F. (1973). Guanidine derivatives in medicine. N Engl J Med 289, 141–146.PubMedGoogle Scholar
  59. De Boer IH, Gorodetskaya I, Young B, Hsu CY & Chertow GM. (2002). The severity of secondary hyperparathyroidism in chronic renal insufficiency is GRF-dependent, race dependent, and associated with cardiovascular disease. J Am Soc Nephrol 13, 2762–2769.PubMedGoogle Scholar
  60. Dean S & Allegretti C. (2003). 25 years of good health. In Patient Line, ed. McKenna CA, pp. 1–3. FMC Medical Services, Lexington, MA.Google Scholar
  61. De Deyn PP, D’Hooge R, Van Bogaert P & Marescau B. (2002). Endogenous guanidino compounds as uremic neurotoxins. Kidney Int 59 (suppl. 78), S77–S83.Google Scholar
  62. De Deyn PP, Marescau B, D’Hodge R, Possemiers I, Nagler J & Mahler C. (1995). Guanidino compound levels in brain regions of non-dialyzed uremic patients. Neurochem Int 27, 227–237.PubMedGoogle Scholar
  63. Deferrari G. (1981). Brain metabolism of amino acids and ammonia in patients with chronic renal insufficiency. Kidney Int 20, 505.PubMedGoogle Scholar
  64. del Zoppo GJ. (1995). Acute stroke – on the theshold of a therapy. New Engl J Med 333, 1632–1633.PubMedGoogle Scholar
  65. Dhondt A, Vanholder R, van Beisen W & Lameire N. (2000). The removal of uremic toxins. Kidney Int 58 (Suppl. 76), S47–S59.Google Scholar
  66. Dunea G, Mahurkar SD & Mamdami B. (1978). Role of aluminum in dialysis dementia. Ann Intern Med 88, 502–504.PubMedGoogle Scholar
  67. Evans RW, Rader B & Manninen DL. (1990). The quality of life of hemodialysis reciepients treated with recombinant human erythropoietin. JAMA 263.Google Scholar
  68. Faden AI, Demediuk P, Panter SS & Vink R. (1989). The role of excitatory amino acids and NMDA receptors in traumatic brain injury. Science 244, 798–800.PubMedGoogle Scholar
  69. Farrar G, Altmann P, Welch S, Wychrij O, Ghose B, Lejeune J, Corbett J, Prasher J & Blair JA. (1990). Defective gallium-transferrin binding in Alzheimer disease and Down syndrome: Possible mechanism for accumulation of aluminum in brain. Lancet 335, 747–750.PubMedGoogle Scholar
  70. Farrar G, Morton AP & Blair JA. (1988). The intestinal spectiation of gallium: Possible models to describe the bioavailability of aluminum. In Trace Element Analytical Chemistry in Medicine and Biology, Bratter P & Schramel P, pp. 343–347. Walter de Gruyter, Berlin.Google Scholar
  71. Fraser CL & Arieff AI. (1985). Hepatic encephalopathy. N Engl J Med 313, 865–873.PubMedGoogle Scholar
  72. Fraser CL & Arieff AI. (1988a). Nervous system complications in uremia. Ann Intern Med 109, 143–153.Google Scholar
  73. Fraser CL & Arieff AI. (1988b). Nervous system manifestations of renal failure. In Diseases of the Kidney, 4th edn, Schrier RW & Gottschalk CW, pp. 3063–3092. Little, Brown, Boston, MA.Google Scholar
  74. Fraser CL & Arieff AI. (1993). Nervous system manifestations of renal failure. In Diseases of the Kidney, 5th edn, Schrier RW & Gottschalk CW, pp. 2789–2816. Little, Brown, Boston, MA.Google Scholar
  75. Fraser CL & Arieff AI. (1994). Metabolic encephalopathy as a complication of renal failure: Mechanisms and mediators. In New Horizons: The Science and Practice of Acute Medicine, 5th edn, Matuschak GM, pp. 518–526. Williams & Wilkins, Baltimore.Google Scholar
  76. Fraser CL & Arieff AI. (1995). Metabolic encephalopathy as a complication of acid base, and electrolyte disorders. In Fluid, Electrolyte and Acid-Base Disorders, 2nd edn, Arieff AI & DeFronzo RA, pp. 685–740. Churchill Livingstone, New York.Google Scholar
  77. Fraser CL & Arieff AI. (1999). Neuropsychiatric complications of uremia. In Therapy in Nephrology and Hypertension, Brady HR & Wilcox CS, pp. 488–490. W.B. Saunders, Philadelphia.Google Scholar
  78. Garruto RM, Fukatsu R, Yanagihara R, Gajdusek DC, Hook G & Fiori CE. (1983). Imaging of calcium and aluminum in neurofibrillary tangle-bearing neurons in parkinsonism-dementia of Guam. Proc Natl Acad Sci USA 81, 1875–1879.Google Scholar
  79. Gilli P & Bastiani P. (1983). Cognitive function and regular dialysis treatment. Clin Nephrol 19, 188–192.PubMedGoogle Scholar
  80. Gines P, Tito L, Arroyo V & Planas J. (1988). Randomized comparative study of therapeutic paracentesis with and without intravenous albumin in cirrhosis. Gastroenterology 94, 1493–1502.PubMedGoogle Scholar
  81. Giovannetti S, Balestri PL & Barsotti G. (1973). Methylguanidine in uremia. Arch Intern Med 131, 709.PubMedGoogle Scholar
  82. Go AS, Chertow GM, Fan D, McCulloch CE & Hsu C. (2004). Chronic kidney disease and the risks of death, cardiovascular events, and hospitalization. New Engl J Med 351, 1296–1305.PubMedGoogle Scholar
  83. Goldstein DA & Massry SG. (1980). The relationship between the abnormalities in EEG and blood levels of parathyroid hormone in dialysis patients. J Clin Endocrinol Metab 51, 130.PubMedGoogle Scholar
  84. Good PF & Perl DP. (1988). A lasar microprobe mass analysis study of aluminum distribution in the cerebral cortex of dialysis encephalopathy. J Neuropathol Exp Neurol 47, 321.Google Scholar
  85. Goodman WG, Gilligan J & Horst R. (1984). Short term aluminum administration in the rat: Effects on bone formation and relationship to renal osteomalacia. J Clin Invest 73, 171.PubMedGoogle Scholar
  86. Graf H, Stummvoll HK & Messinger V. (1981). Aluminum removal by hemodialysis. Kidney Int 19, 587.PubMedGoogle Scholar
  87. Greenberg MD. (1978). Brain damage in hemodialysis patients. Dialy Transplant 7, 238.Google Scholar
  88. Grimm G, Stockenhuber F, Schneeweiss B, Madl C, Zeitlhofer J & Schneider B. (1990). Improvement of brain fuunction in hemodialysis patients treated with erythropoietin. Kidney Int 38, 480–486.PubMedGoogle Scholar
  89. Grushkin CM, Korsch B & Fine RN. (1972). Hemodialysis in small children. JAMA 221, 869.PubMedGoogle Scholar
  90. Guisado R, Arieff AI, Massry SG, Lazarowitz V & Kerian A. (1975). Changes in the electroencephalogram in acute uremia. Effects of parathyroid hormone and brain electrolytes. J Clin Invest 55, 738–745.PubMedGoogle Scholar
  91. Gusbeth-Tatomir P, Boisteanu D, Seica A, Buga C & Covic A. (2007). Sleep disorders: A systematic review of an emerging major clinical issue in renal patients. Int Urol Nephrol 39, 1217–1226.PubMedGoogle Scholar
  92. Guy J, Johnston PK, Corbett JJ, Day AL & Glaser JS. (1990). Treatment of visual loss in pseudotumor cerebri associated with uremia. Neurology 40, 28–32.PubMedGoogle Scholar
  93. Haag-Weber M. (1998). AGE-modified proteins in renal failure. In Critical Care Nephrology, Ronco C & Bellomo R, pp. 878–883. Kluwer, Hingham, MA.Google Scholar
  94. Heath H, Hodgson SF & Kennedy MA. (1980). Primary hyperparathyroidism: Incidence, morbidity, and potential impact in a community hospital. New Engl J Med 302, 189–193.PubMedGoogle Scholar
  95. Herrmann HC, Chang G, Klugherz BD & Mahoney PD. (2000). Hemodynamic effects of sildenafil in men with severe coronary artery disease. New Engl J Med 342, 1622–1626.PubMedGoogle Scholar
  96. Hershey CO, Ricanati ES, Hershey LA, Varnes AW, Lavin PJM & Strain WH. (1983). Silicon as a potential uremic neurotoxin: Trace element analysis in patients with renal failure. Neurology 33, 786–789.PubMedGoogle Scholar
  97. Herzog CA, Littrell K, Arko C, Frederick PD & Blaney M. (2007). Clinical characteristics of dialysis patients with acute myocardial infarction in the United States. Circul 116, 1465–1472.Google Scholar
  98. Honig LS & Rosenberg RN. (2000). Apoptosis and neurologic disease. Am J Med 108, 317–330.PubMedGoogle Scholar
  99. Joy MS & Finn WF. (2003). Randomized, double-blind, placebo-controlled, dose-titratio, phase III study assessing the efficacy and tolerability of lanthanum carbonate: A new phosphate binder for the treatment of hyperphosphatemia. Am J Kidney Dis 42, 96–107.PubMedGoogle Scholar
  100. Kaysen GA. (2001). The microinflamatory state in uremia: Causes and potential consequences. J Am Soc Nephrol 12, 1549–1557.PubMedGoogle Scholar
  101. Kiley JE, Woodruff MW & Pratt KL. (1976). Evaluation of encephalopathy by EEG frequency analysis in chronic dialysis patients. Clin Nephrol 5, 245.PubMedGoogle Scholar
  102. Kjellstrand CM, Arieff AI, Friedman EA, Furst P, Henderson LW & Massry SG. (1979). Inadequacy of dialysis: Why patients are not well. Trans Am Soc Artif Intern Organs XXV, 518–520.Google Scholar
  103. Koenig H, Goldstone AD, Lu CY & Trout JJ. (1988). Polyamines: Transducers of osmotic signals at the blood-brain barrier. Proc Amer Soc Neurochem 19, 79.Google Scholar
  104. Koren-Morag N, Goldbourt U & Tanne D. (2006). Renal dysfunction and risk of ischemic stroke or TIA in patients with cardiovascular disease. Neurol 67, 224–228.Google Scholar
  105. Korzets Z, Zeltzer E, Rathaus M, Manor R & Bernheim J. (1998). Uremic optic neuropathy. A uremic manifestation mandating dialysis. Am J Nephrol 18, 240–242.PubMedGoogle Scholar
  106. Kucharczyk W, Brant-Zawadzki M & Norman D. (1985). Magnetic resonance imaging of the central nervous system–An update. West J Med 142, 54–62.PubMedGoogle Scholar
  107. Kumar M, Liu GJ, Floyd RA & Grammas P. (1996). Anoxic inujury of endothelial cells increses production of nitric oxide and hydroxyl radicals. Biochem Biophys Res Comm 219, 497–501.PubMedGoogle Scholar
  108. Lamberts SWJ, van den Beld AW & van der Lely A. (1997). The endocrinology of aging. Science 278, 419–424.PubMedGoogle Scholar
  109. Leland J. (1997). A pill for impotence? Newsweek Nov. 17, 62–68.Google Scholar
  110. Leonard A & Shapiro FL. (1975). Subdural hematoma in regularly hemodialyzed patients. Ann Intern Med 82, 650–658.PubMedGoogle Scholar
  111. Levin GE & Baron DN. (1977). Leucocyte intracellular pH in patients with metabolic acidosis or renal failure. Clin Sci (Oxford) 52, 325.Google Scholar
  112. Lipton SA & Rosenberg PA. (1994). Excitatory amino acids as a final common pathway for neurologic disorders. New Engl J Med 330, 613–622.PubMedGoogle Scholar
  113. Lonnemann G. (2000). Chronic inflamation in hemodialysis: The role of contaminated dialysate. Blood Purif 18, 214–223.PubMedGoogle Scholar
  114. Luxenberg J, Feigenbaum LZ & Aron JM. (1984). Reversible long-standing dementia with normocalcemic hyperparathyroidism. J Am Geriat Soc 32, 546–547.PubMedGoogle Scholar
  115. Mahoney CA & Arieff AI. (1982). Uremic encephalopathies: Clinical, biochemical and experimental features. Amer J Kidney Dis 2, 324–336.Google Scholar
  116. Mahoney CA, Arieff AI, Leach WJ & Lazarowitz VC. (1983). Central and peripheral nervous system effects of chronic renal failure. Kidney Int 24, 170–177.PubMedGoogle Scholar
  117. Mahoney CA, Sarnacki P & Arieff AI. (1984). Uremic encephalopathy: Role of brain energy metabolism. Am J Physiol 247 (Renal Fluid Electrolyte Physiol. 16), F527–F532.PubMedGoogle Scholar
  118. Mahurkar SD, Dkar SK, Salta R, Myers L, Smith LC & Dunea G. (1973). Dialysis dementia. Lancet 1, 1412–1415.PubMedGoogle Scholar
  119. Mahurkar SD, Myers L, Cohen J, Kamath RV & Dunea G. (1978). Electroencephalographic and radionucleotide studies in dialysis dementia. Kidney Int 13, 306–315.PubMedGoogle Scholar
  120. Mai ML, Emmett M, Sheikh MS, Santa Ana CA, Schiller L & Fordtran JS. (1989). Calcium acetate, an effective phosphorus binder in patients with renal failure. Kidney Int 36, 690–695.PubMedGoogle Scholar
  121. Makita Z, Radoff S, Rayfield EJ, Yang Z, Skolnik E, Delaney V, Friedman EA, Cerami A & Vlassara H. (1991). Advanced glycosylation end products in patients with diabetic nephropathy. N Engl J Med 325, 836–842.PubMedGoogle Scholar
  122. Malluche HH, Smith AJ & Abreo K. (1984). The use of deferoxamine in the management of aluminum accumulation in bone in patients with renal failure. N Engl J Med 311, 140.PubMedGoogle Scholar
  123. Martinez-Vea A, Salvado E, Bardaji A, Gutierrez C, Ramos A & Garcia C. (2006). Silent cerebral white matter lesions and their relationship with vascular risk factors in middle-aged predialysis patients with CKD. Am J Kidney Dis 47, 241–250.PubMedGoogle Scholar
  124. Maschio G, Bazzato G, Bertaglia E, Sardini D & Mioni G. (1970). Intracellular pH and electrolyte content of skeletal muscle in patients with chronic renal acidosis. Nephron 7, 481–487.PubMedGoogle Scholar
  125. Mattana J, Effiong C, Gooneratne R & Singhal PC. (1998). Outcome of stroke in patients undergoing hemodialysis. Arch Intern Med 158, 537–541.PubMedGoogle Scholar
  126. Mauer M, Fioretta P, Woredekal Y & Friedman EA. (2001). Diabetic nephropathy. In Diseases of the Kidney, 7th edn, Schrier RW & Gottschalk CW, pp. 2083–2127. J.B. Lippincott, Philadelphia.Google Scholar
  127. Mazzuchi N, Carbonell E & Fernandez-Caen J. (2000). Importance of blood pressure control in hemodialysis patient survival. Kidney Int 58, 2147–2154.PubMedGoogle Scholar
  128. Meeus F, Kourilsky O, Guerin AP, Gaudry C, Marchais SJ & London GM. (2000). Pathophysiology of cardiovascular disease in hemodialysis patients. Kidney Int 58 (Suppl. 76), S140–S147.Google Scholar
  129. Meyer TW & Hostetter TH. (2007). Uremia. New Engl J Med 357, 1316–1325.PubMedGoogle Scholar
  130. Minkoff L, Gaertner M, Darah C, Mercier C & Levin ML. (1972). Inhibition of brain sodium-potassium ATPase in uremic rats. J Lab Clin Med 80, 71–78.PubMedGoogle Scholar
  131. Miyata T, Kirokawa K & van Ypersele de Strihou C. (2000). Relevance of oxidative and carbonyl stress to long-term uremic complications. Kidney Int 58 (Suppl. 76), S120–S125.Google Scholar
  132. Miyata T, Sugiyama S, Saito A & Kirokawa K. (2001). Reactive carbonyl compounds related uremic toxicity (carbonyl stress). Kidney Int 59 (Suppl. 78), S25–S31.Google Scholar
  133. Miyata T, van Ypersele de Strihou C, Ueda Y, Ichimori K & Kirokawa K. (2002). Angiotensin II receptor antagonists and angiotensin-converting enzyme inhibitors lower in vitro the formation of advanced glycation end products: Biochemical mechanisms. J Am Soc Nephrol 13, 2478–2487.PubMedGoogle Scholar
  134. Moe SM & Sprague SM. (1994). Uremic encephalopathy. Clin Nephrol 42, 251–256.PubMedGoogle Scholar
  135. Monk RD & Bennett DA. (2006). Reno-cerebrovascular disease? Neurol 67, 196–198.Google Scholar
  136. Moreno F, Sanz-Guajardo D, Lopez-Gomez J, Jofre R & Valderrabano F. (2000). Increasing the hematocrit has a beneficial effect on quality of life and is safe in selected hemodialysis patients. J Am Soc Nephrol 11, 335–342.PubMedGoogle Scholar
  137. Murray AM, Pederson SI, Tupper DE, Hochhalter AK, Miller WA, Zaun D, Collins AJ, Kane R & Foley RN. (2007). Acute variation in cognitive function in hemodialysis patients. Am J Kidney Dis 50, 270–278.PubMedGoogle Scholar
  138. Murray AM, Tupper DE, Knopman DS & Gilbertson DT. (2006). Cognitive impairment in hemodialysis patients is common. Neurology 67, 216–223.PubMedGoogle Scholar
  139. Naganuma T, Uchida J & Tsuchida K. (2005). Silent cerebral infarction predicts vascular events in hemodialysis patients. Kidney Int 67, 2434–2439.PubMedGoogle Scholar
  140. Nathan HP, Hellstrom WJG & Kaiser FE. (1997). Treatment of men with erectile dysfunction with transurethral alprostadil. New Engl J Med 336, 1–7.Google Scholar
  141. Ogura T, Makinodan A, Kubo T, Hayashida T & Hirasawa Y. (2001). Electrophysiological course of uraemic neuropathy in haemodialysis patients. Postgrad Med J 77, 451–454.PubMedGoogle Scholar
  142. Okada J, Yoshikawa K, Matsuo H & Oouchi M. (1991). Reversible MRI and CT findings in uremic encphalopathy. Neuoradiology 33, 524–526.Google Scholar
  143. Olsen S. (1961). The brain in uremia. Acta Psychiat Scand 36 (Suppl. 156), 1–128.Google Scholar
  144. Palmer BF. (1999). Sexual dysfunction in uremia. J Am Soc Nephrol 10, 1381–1388.PubMedGoogle Scholar
  145. Palmer BF. (2003). Sexual dysfunction in men and women with chronic kidney disease and end-stage kidney disease. Adv Ren Replace Ther 10, 48–60.PubMedGoogle Scholar
  146. Panichi V, Migliori M, De Pietro S, Taccola D & Andreini B. (2000). The link of biocompatibility to cytokine production. Kidney Int 58 (Suppl. 76), S96–S103.Google Scholar
  147. Papadakis MA & Arieff AI. (1987). Unpredictability of clinical evaluation of renal function in cirrhosis. Amer J Med 82, 945–952.PubMedGoogle Scholar
  148. Papageorgiou C, Ziroyannis P & Vathylakis J. (1982). A comparative study of brain atrophy by computerized tomography in chronic renal failure and chronic hemodialysis. Acta Neurol Scand 66, 378–384.PubMedGoogle Scholar
  149. Pereira AA, Weiner DE, Scott T, Chandra P, Bluestein R, Griffith J & Sarnak MJ. (2007). Subcortical cognitive impairment in dialysis patients. Hemodial Int 11, 309–314.PubMedGoogle Scholar
  150. Pereira AA, Weiner DE, Scott T & Sarnak MJ. (2005). Cognitive function in dialysis patients. Am J Kidney Dis 45, 448–462.PubMedGoogle Scholar
  151. Perl DP & Brody AR. (1980). Alzheimer’s disease: X-ray spectrometric evidence of aluminum accumulation in neurofibrillary tangle-bearing neurons. Science 208, 297–299.PubMedGoogle Scholar
  152. Perl DP & Good PF. (1990). Microprobe studies of aluminum accumulation in association with human central nervous system disease. Environ Geochem Health 12, 97–102.Google Scholar
  153. Perl J, Unruh ML & Chan CT. (2006). Sleep disorders in end-stage renal disease; ‘Markers of inadequate dialysis?’ Kidney Int 70, 1687–1693.PubMedGoogle Scholar
  154. Perry TL, Yong VW, Kish SJ, Ito M, Foulks JG, Godolphin WJ & Sweeney VP. (1985). Neurochemical abnormalities in brain of renal failure patients treated by repeated hemodialysis. J Neurochem 45, 1043–1048.PubMedGoogle Scholar
  155. Pierides AM, Edwards WG Jr, Cullum UX Jr, Mc call JT & Ellis HA. (1980). Hemodialysis encephalopathy with osteomalacic fractures and muscle weakness. Kidney Int 18, 115.PubMedGoogle Scholar
  156. Pliskin NH, Yurk HM, Ho LT & Umans JG. (1996). Neurocognitive function in chronic hemodialysis patients. Kidney Int 49, 1435–1440.PubMedGoogle Scholar
  157. Porte FK, Johnson WJ & Klass DW. (1973). Prevention of dialysis disequilibrium syndrome by use of high sodium concentration in the dialysate. Kidney Int 3, 327.Google Scholar
  158. Rasmussen H. (1986). The calcium messenger system, parts I and II. New Engl J Med 314, 1094–1101 and 1164–1170.PubMedGoogle Scholar
  159. Rifat SL, Eastwood MR, McLachlan DRC & Corey PN. (1990). Effect of exposure of miners to aluminum powder. Lancet 336, 1162–1165.PubMedGoogle Scholar
  160. Rodrigo F, Shideman J, McHugh R, Buselmeier T & Kjellstrand C. (1977). Osmolality changes during hemodialysis: Natural history, clinical correlations, and influence of dialysate glucose and intravenous mannitol. Ann Intern Med 86, 554–561.PubMedGoogle Scholar
  161. Ronco C, Brendolan A & Bellomo R. (1998). Current technology for continuous renal replacement therapies. In Critical Care Nephrology, Ronco C & Bellomo R, pp. 1269–1308. Kluwer, Hingham, MA.Google Scholar
  162. Rotter W & Roettger P. (1974). Comparative pathologic-anatomic study of cases of chronic global renal insufficiency with and without preceding hemodialysis. Clin Nephrol 1, 257.Google Scholar
  163. rt-PA Stroke Study Group N. (1995). Tissue plasminogen activator for acute ischemic stroke. New Engl J Med 333, 1581–1587.Google Scholar
  164. Sato Y, Kaji M, Metoki N, Satoh K & Iwamoto J. (2003). Does compensatory hyperparathyroidism predispose to ischemic stroke? Neurology 60, 626–629.PubMedGoogle Scholar
  165. Savazzi GM. (1988). Pathogenesis of cerebral atrophy in uraemia. Nephron 49, 94–103.PubMedGoogle Scholar
  166. Savazzi GM, Cusamo F, Vinci S & Allegri L. (1995). Progression of cerebral atrophy in patients on regular hemodialysis treatment: Long-term follow-up with cerebral computed tomography. Nephron 69, 29–33.PubMedGoogle Scholar
  167. Schievink WI. (2001). Spontaneous dissection of the carotid and vertebral arteries. New Engl J Med 344, 898–906.PubMedGoogle Scholar
  168. Schrier RW & Wang W. (2004). Acute renal failure and sepsis. New Engl J Med 351, 159–169.PubMedGoogle Scholar
  169. Schulman G & Himmelfarb J. (2004). Hemodialysis. In Brenner & Rector’s The Kidney, 7th edn, Brenner BM, pp. 2563–2624. W.B. Saunders, Philadelphia, PA.Google Scholar
  170. Schulz JB & Arieff AI. (2003). Metabolic and toxic encephalopathies. In Neurological Disorders: Course and Treatment, 2nd edn, eds. Brandt T, Caplan LR, Dichgans J, Diener HC & Kennard C, pp. 991–1010. Academic Press, London.Google Scholar
  171. Scribner BH & Babb AL. (1975). Evidence for toxins of “middle” molecular weight. Kidney Int 7 (Suppl 3), S349.Google Scholar
  172. Sehgal AR, Grey SF, DeOreo PB & Whitehouse PJ. (1997). Prevalence, recognition, and implications of mental impairment among hemodialysis patients. Am J Kidney Dis 30, 41–49.PubMedGoogle Scholar
  173. Sharad G, Saran R & Nolph KW. (1998). Indications, contraindications and complications of peritoneal dialysis in the critically ill. In Critical Care Nephrology, Ronco C & Bellomo R, pp. 1373–1382. Kluwer, Hingham, MA.Google Scholar
  174. Sherman DG, Atkinson RP & Chippendale T. (2000). Intravenous ancrod for treatment of acute ischemic stroke. JAMA 283, 2395–2403.PubMedGoogle Scholar
  175. Shik J & Parfrey PS. (2005). The clinical edidemiology of cardiovascular disease in chronic kidney disease. Curr Opin Nephrol Hypertens 14, 550–557.PubMedGoogle Scholar
  176. Siddiqui JY, Fitz AE & Lawton RL. (1970). Causes of death in patients receiving long-term hemodialysis. JAMA 212, 1350.PubMedGoogle Scholar
  177. Slatopolsky E, Martin K & Hruska K. (1980). Parathyroid hormone metabolism and its potential as a uremic toxin. Am J Physiol 239, F1–F12.PubMedGoogle Scholar
  178. Slatopolsky EA. (1999). Renagel®, a nonabsorbed calcium- and aluminum-free phosphate binder, lowers serum phosphorus and parathyroid hormone. Kidney Int 55, 299–307.PubMedGoogle Scholar
  179. Snow V, Weiss KB & LeFevre M. (2003). Management of newly detected atrial fibrillation. Ann Intern Med 139, 1009–1017.PubMedGoogle Scholar
  180. Sprague SM, Corwin HL, Tanner CM, Wilson RS, Green BJ & Goetz CG. (1988). Relationship of aluminum to neurocognitive dysfunction in chronic dialysis patients. Arch Intern Med 148, 2169–2172.PubMedGoogle Scholar
  181. Study Group E. (1996). Thrombolytic therapy with streptokinase in acute ischemic stroke. New Engl J Med 335, 145–150.Google Scholar
  182. Takabatake T, Ohta H, Ishida Y, Hara H, Ushiogi Y & Hattori N. (1988). Low serum creatinine levels in severe hepatic disease. Arch Intern Med 148, 1313–1315.PubMedGoogle Scholar
  183. Takaki J, Nishi T, Nangaku M, Shimoyama H, Inada T, Matsuyama N, Kumano H & Kuboki T. (2003). Clinical and psychological aspects of restless legs syndrome in uremic patients on hemodialysis. Am J Kidney Dis 41, 833–839.PubMedGoogle Scholar
  184. Taki K, Takayama F, Tsuruta Y & Niwa T. (2006). Oxidative stress, advanced glycation end product and coronary artery calcification in hemodialysis patients. Kidney Int 70, 218–224.PubMedGoogle Scholar
  185. Teschan PE & Arieff AI. (1985). Uremic and dialysis encephalopathies. In Cerebral Energy Metabolism and Metabolic Encephalopathy, ed. McCandless DW, pp. 263–285. Plenum, New York.Google Scholar
  186. Teschan PE, Bourne JR & Reed RB. (1983). Electrophysiological and neurobehavioral responses to therapy: The national cooperative dialysis study. Kidney Int 23, 558.Google Scholar
  187. Teschan PE, Ginn HE, Bourne JR, Ward JW, Hamel B, Nunnally JC, Musso M & Vaughn WK. (1979). Quantitative indices of clinical uremia. Kidney Int 15, 676–697.PubMedGoogle Scholar
  188. Thodis E, Anninos PA, Pasadakis P, Adamopoulos AV, Panagoutsos S & Vargemezis V. (1992). Evaluation of CNS function in CAPD patients using magnetoencephalography (MEG). Adv Perit Dial 8, 181–184.PubMedGoogle Scholar
  189. Tizianello A, Deferrari G, Gurreri G & Acquarone N. (1977). Effects of metabolic alkalosis, metabolic acidosis and uraemia on whole-body intracellular pH in man. Clin Sci Mol Med (Oxford) 52, 125–135.Google Scholar
  190. Toyoda K, Fujii K, Fujimi S, Kumai Y, Tsuchimochi H, Ibayashi S & Lida M. (2005). Stroke in patients on maintainance hemodialysis: A 22-year single center study. Am J Kidney Dis 45, 1058–1066.PubMedGoogle Scholar
  191. Van den Noort S, Eckel RE, Brine K & Hrdlicka JT. (1968). Brain metabolism in uremic and adenosine-infused rats. J Clin Invest 47, 2133–2142.PubMedGoogle Scholar
  192. Vanholder R. (1998a). Low molecular weight uremic toxins. In Critical Care Nephrology, Ronco C & Bellomo R, pp. 855–868. Kluwer, Hingham, MA.Google Scholar
  193. Vanholder R. (1998b). Pathogenesis of uremic toxicity. In Critical Care Nephrology, Ronco C & Bellomo R, pp. 845–853. Kluwer, Hingham, MA.Google Scholar
  194. Vanholder R, De Smet R & Glorieux G. (2003). Review on uremic toxins: Classification, concentration, and interindividual variability. Kidney Int 63, 1934–1943.PubMedGoogle Scholar
  195. Vanholder R, De Smet R & Lameire N. (2001). Protein-bound uremic solutes: The forgotten toxins. Kidney int 59 (Suppl. 78), S266–S270.Google Scholar
  196. Verkman AS & Fraser CL. (1986). Water and non-electrolyte permeability in brain synaptosomes isolated from normal and uremic rats. Am J Physiol 250, R306–R312.PubMedGoogle Scholar
  197. Vexler ZS, Roberts TPL, Bollen AW, Derugin N & Arieff AI. (1997). Transient cerebral ischemia: Association of apoptosis induction with hypoperfusion. J Clin Invest 99, 1453–1459.PubMedGoogle Scholar
  198. Wang HC, Brown P & Lees AJ. (1998). Acute movement disorders with bilateral basal ganglia lesions in uremia. Movement Dis 13, 952–957.PubMedGoogle Scholar
  199. Wang HC, Hsu JL & Shen YY. (2004). Acute bilateral basal ganglia lesions in patients with diabetic uremia: An FDG-PET study. Clin Nucl Med 29, 475–478.PubMedGoogle Scholar
  200. Ward MK, Feest TG, Ellis HA, Parkinson IS & Keer DN. (1978). Osteomalacia dialysis osteodystrophy: Evidence for a water-borne aetiological agent, probably aluminum. Lancet 1, 841.PubMedGoogle Scholar
  201. Winchester JF & Audia P. (2006). Extracorporeal strategies for the removal of middle molecules. Semin Dial 19, 110–114.PubMedGoogle Scholar
  202. Winkelmayer WC, Eigner M, Berger O, Grisold W & Leithner C. (2001). Optic neuropathy in uremia. Am J Kidney Dis 37, E23.PubMedGoogle Scholar
  203. Wratten ML, Tetta C, Ursini F & Sevanian A. (2000). Oxidant stress in hemodialysis: Prevention and treatment strategies. Kidney Int 58 (Suppl. 76), S126–S132.Google Scholar
  204. Yasuda H & Nakajiima A. (1993). Brain protection against ischemic injury by nizofenone. Cerebrovasc Brain Metabol Rev 5, 264–268.Google Scholar
  205. Yu SP, Yeh CH, Strasser M, Tian M & Choi DW. (1999). NMDA receptor-mediated K+ efflux and neuronal apoptosis. Science 284, 336–338.PubMedGoogle Scholar
  206. Zimmerman JS & Herringer JS. (1999). Inflamation enhances cardiovascular risk and mortality in hemodialysis patients. Kidney Int 55, 648–658.Google Scholar
  207. Zoccali C, Mallamaci F & Tripipepi G. (2003). Inflamation and atherosclerosis in end-stage renal disease. Blood Purif 21, 29–36.PubMedGoogle Scholar

Copyright information

© Springer Science+Business Media, LLC 2009

Authors and Affiliations

  • Allen I. Arieff
    • 1
  1. 1.Department of Medicine, University of California School of Medicine, San Francisco CaliforniaCedars-Sinai Medical CenterLos AngelesUSA

Personalised recommendations